EDAP's Ablatherm® Robotic HIFU Treatments Performed at University of Minnesota
February 27 2017 - 7:31AM
EDAP's Ablatherm® Robotic HIFU
Treatments Performed at University of
Minnesota
LYON, France, February 27, 2017 -- EDAP TMS SA (Nasdaq: EDAP),
the global leader in therapeutic ultrasound, today announced the
first prostate ablation treatments performed at the University of
Minnesota, Minneapolis, using the Company's FDA-cleared Ablatherm
Robotic HIFU. The Department of Urology at the University of
Minnesota Medical School is recognized as one of the leading
urology departments in the United States.
Dr. Badrinath Konety, Chair, Department
of Urology University of Minnesota Director, Institute
for Prostate and Urologic Cancers, commented: "We are delighted to
be the first center in the upper Midwest to offer Ablatherm Robotic
HIFU. We find it to be an excellent low morbidity treatment option
for appropriately selected patients with prostate cancer."
Marc Oczachowski, EDAP TMS Chief Executive Officer, added: "We
are very pleased to add the prestigious University of Minnesota to
our list of HIFU centers in the U.S. and to work in close
collaboration with Dr. B. Konety in supporting HIFU adoption among
the urology community. By partnering with HIFU Solution, we
increase the availability of HIFU treatments for U.S. patients by
offering mobile HIFU access to hospitals and clinics. We look
forward to continuing to extend our HIFU education programs
throughout the country to as many American urologists as
possible."
Dr. P. Narayan MD, HIFU Solution Medical Director, commented:
"It is with great pleasure that HIFU Solution, in conjunction with
Urologists and Surgical centers, was able to offer mobile HIFU to
patients of the state of Minnesota, utilizing the innovative
Ablatherm treatment device from EDAP. We will be offering this HIFU
service to many doctors in the urology community around the
country."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and
for treatment of localized prostate cancer in the rest of
the world. HIFU treatment is shown to be a minimally invasive and
effective option for prostatic tissue ablation with a low
occurrence of side effects. Ablatherm is generally recommended for
patients with localized prostate cancer (stages T1-T2) who are not
candidates for surgery or who prefer an alternative option, or for
patients who failed radiotherapy treatment. Ablatherm is approved
for commercial distribution in Europe and other countries including
Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com,
and http://www.hifu-planet.com.
About HIFU Solution
HIFU Solution combines compassionate, highly qualified and
experienced physicians and professionals with pioneering,
noninvasive HIFU technology for the diagnosis and treatment of
prostate cancer to provide unparalleled patient care. The company
aims to provide patients and their families with answers about the
diagnosis and treatment options, and a clear path forward. HIFU
Solution is comprised of a network of twenty-six qualified
physicians placed in ten states. With five centers established on
the East Coast, HIFU Solution plans to launch five more centers in
the Midwest and Western parts of the country. For more information
on the company, please visit http://www.hifusolution.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also
may include, but are not limited to, those described in
the Company's filings with the Securities and Exchange Commission
and in particular, in the sections "Cautionary Statement on
Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F.
Investor Contact
CG CAPITALRich
Cockrell877.889.1972investorrelations@cg.capital
Company Contact
Blandine ConfortInvestor Relations / Legal Affairs EDAP TMS
SA+33 4 72 15 31 50bconfort@edap-tms.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Sep 2023 to Sep 2024